ArticleRSC advances2025
Facile and green synthesis of monodisperse sub-10 nm copper and tin nanoparticles using l-ascorbic acid as the reducing agent.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sustainable Synthesis of Copper Nanoparticles in 3D-Printed Microfluidic Devices: Effect of pH and Mixing Kinetics on Physicochemical Properties.Nanomaterials (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We first optimized a simple and low-cost polyol-based synthesis route for the preparation of stable and monodisperse sub-10 nm copper nanoparticles. Building on this robust approach, we extended the method to tin and succeeded in producing tin nanoparticles that stabilized in an unconventional α-Sn phase, which is remarkable given the metastable character of this phase under ambient conditions. The resulting α-Sn nanoparticles exhibited excellent resistance to oxidation, together with long-term colloidal stability in air, enabling further processing for potential applications. In both cases, inexpensive commercial precursors and mild conditions (80 °C, aqueous or polyol solvents, ascorbic acid as the sole reducing agent, and no inert atmosphere or additional stabilizers) were employed. The nanoparticles were characterized using TEM, UV-visible spectroscopy, ATR-FTIR, ICP-OES, and XPS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.